Semaglutide is generally discussed as a GLP-1 receptor agonist model, Tirzepatide as a dual GIP and GLP-1 receptor agonist model, and Retatrutide as a triple receptor agonist model involving GLP-1, GIP, and glucagon receptor pathways
Mounjaro, however, directly reduces appetite and slows gastric emptying, leading to reduced food intake and more significant weight loss that targets visceral fat (up to 40% reduction in some studies)
Clinical trials and real-world patient reports suggest that cognitive symptoms occur in roughly 515% of semaglutide users, though many cases are mild and self-limiting
While GLP-1s are commonly used by perimenopausal women, this population has been largely ignored in studies of the drugs' risks and benefits
Semaglutide is widely available through prescription in Canada for approved indications
If your main goal is to start and sustain GLP-1 treatment with predictable pricing, recurring support, and nutrition access, Mochis model is often simpler